Przemyslaw Twardowski
About
Przemyslaw Twardowski is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology.
According to data from OpenAlex, Przemyslaw Twardowski has authored 113 papers receiving a total of 4.3k indexed citations (citations by other indexed papers that have themselves been cited), including 73 papers in Pulmonary and Respiratory Medicine, 63 papers in Oncology and 27 papers in Molecular Biology. Recurrent topics in Przemyslaw Twardowski's work include Prostate Cancer Treatment and Research (51 papers), Cancer Immunotherapy and Biomarkers (17 papers) and Renal cell carcinoma treatment (16 papers). Przemyslaw Twardowski is often cited by papers focused on Prostate Cancer Treatment and Research (51 papers), Cancer Immunotherapy and Biomarkers (17 papers) and Renal cell carcinoma treatment (16 papers). Przemyslaw Twardowski collaborates with scholars based in United States, Canada and United Kingdom. Przemyslaw Twardowski's co-authors include Neeraj Agarwal, Primo N. Lara, Kim N., Oliver Sartor, Neal D. Shore, Jinyu Kang, Carrie A. Adelman, Antoine Thiery-Vuillemin, Fred Saad and Joaquı́n Mateo and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and Journal of Clinical Oncology.
In The Last Decade
Przemyslaw Twardowski
110 papers receiving 4.2k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Przemyslaw Twardowski United States | 29 | 2.4k | 2.2k | 1.6k | 1.2k | 523 | 113 | 4.3k | ||
| Antoine Thiery-Vuillemin France | 24 | 2.4k 1.0× | 2.0k 0.9× | 1.2k 0.8× | 985 0.8× | 292 0.6× | 155 | 3.7k | ||
| Michael L. Cher United States | 42 | 2.5k 1.0× | 2.0k 0.9× | 1.9k 1.2× | 1.6k 1.3× | 590 1.1× | 165 | 5.5k | ||
| Niven Mehra Netherlands | 31 | 2.6k 1.1× | 2.3k 1.1× | 1.5k 1.0× | 1.3k 1.0× | 305 0.6× | 178 | 4.4k | ||
| Roberto Iacovelli Italy | 34 | 2.6k 1.1× | 2.1k 1.0× | 1.5k 1.0× | 1.2k 1.0× | 712 1.4× | 224 | 4.6k | ||
| Begoña Mellado Spain | 36 | 2.2k 0.9× | 1.9k 0.9× | 2.0k 1.3× | 1.1k 0.9× | 947 1.8× | 180 | 4.7k | ||
| Ulrik Lassen Denmark | 36 | 1.6k 0.6× | 2.2k 1.0× | 1.7k 1.1× | 1.0k 0.8× | 644 1.2× | 253 | 4.9k | ||
| Barbara J. Gitlitz United States | 37 | 2.8k 1.2× | 1.9k 0.9× | 2.2k 1.4× | 855 0.7× | 752 1.4× | 118 | 4.5k | ||
| Joshi J. Alumkal United States | 31 | 2.8k 1.2× | 1.7k 0.8× | 1.8k 1.1× | 1.3k 1.0× | 208 0.4× | 136 | 4.7k | ||
| Matthew M. Cooney United States | 24 | 3.6k 1.5× | 1.8k 0.8× | 1.0k 0.7× | 1.1k 0.9× | 367 0.7× | 86 | 5.2k | ||
| Joaquı́n Mateo United Kingdom | 34 | 3.2k 1.3× | 3.3k 1.5× | 2.1k 1.4× | 1.8k 1.5× | 310 0.6× | 148 | 6.1k |
Countries citing papers authored by Przemyslaw Twardowski
Since
Specialization
Citations
This map shows the geographic impact of Przemyslaw Twardowski's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Przemyslaw Twardowski with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Przemyslaw Twardowski more than expected).
Fields of papers citing papers by Przemyslaw Twardowski
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Przemyslaw Twardowski. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Przemyslaw Twardowski. The network helps show where Przemyslaw Twardowski may publish in the future.
Co-authorship network of co-authors of Przemyslaw Twardowski
This figure shows the co-authorship network connecting the top 25 collaborators of Przemyslaw Twardowski. A scholar is included among the top collaborators of Przemyslaw Twardowski based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Przemyslaw Twardowski. Przemyslaw Twardowski is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Wang, Xiaoqiang, Shoubao Ma, Przemyslaw Twardowski, et al.. (2024). Abstract 1831: Reduction of PMN-MDSC level/activity following the consumption of white button mushroom in prostate cancer murine models and patients: A translational study to mitigate cancer progression. Cancer Research. 84(6_Supplement). 1831–1831.
2.
Armstrong, Andrew J., Amy K. Taylor, Michael Haffner, et al.. (2024). Germline and somatic testing for homologous repair deficiency in patients with prostate cancer (part 1 of 2). Prostate Cancer and Prostatic Diseases. 28(3). 652–661.
3.
Lara, Primo N., Edward Mayerson, Erik Gertz, et al.. (2023). Bone Biomarkers and Subsequent Survival in Men with Hormone-sensitive Prostate Cancer: Results from the SWOG S1216 Phase 3 Trial of Androgen Deprivation Therapy with or Without Orteronel. European Urology. 85(2). 171–176.
4.
Agarwal, Neeraj, Catherine M. Tangen, Maha Hussain, et al.. (2022). Orteronel for Metastatic Hormone-Sensitive Prostate Cancer: A Multicenter, Randomized, Open-Label Phase III Trial (SWOG-1216). Journal of Clinical Oncology. 40(28). 3301–3309.
5.
Lara, Primo N., Edward Mayerson, Erik Gertz, et al.. (2022). Bone biomarkers and overall survival (OS) in men with advanced hormone-sensitive prostate cancer (HSPC): Results from SWOG S1216, a phase III trial of ADT +/- orteronel.. Journal of Clinical Oncology. 40(16_suppl). 5071–5071.
6.
Bono, Johann S. de, Joaquı́n Mateo, Karim Fizazi, et al.. (2020). Olaparib for Metastatic Castration-Resistant Prostate Cancer. New England Journal of Medicine. 382(22). 2091–2102.
7.
Hussain, Maha, Joaquı́n Mateo, Karim Fizazi, et al.. (2020). Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer. New England Journal of Medicine. 383(24). 2345–2357.
8.
Crawford, E. David, Jason Hafron, Scott T. Tagawa, et al.. (2020). Impact of Late Dosing on Testosterone Suppression with 2 Different Leuprolide Acetate Formulations: In Situ Gel and Microsphere. An Analysis of United States Clinical Data. The Journal of Urology. 205(2). 554–560.
9.
Hahn, Andrew W., David D. Stenehjem, Anitha Alex, et al.. (2019). Time from definitive therapy to onset of metastatic disease predicts outcomes in men with metastatic hormone sensitive prostate cancer. Urologic Oncology Seminars and Original Investigations. 37(6). 352.e19–352.e24.
10.
Bono, Johann S. de, Maha Hussain, Antoine Thiery-Vuillemin, et al.. (2017). PROfound: A randomized Phase III trial evaluating olaparib in patients with metastatic castration-resistant prostate cancer and a deleterious homologous recombination DNA repair aberration.. Journal of Clinical Oncology. 35(15_suppl). TPS5091–TPS5091.
11.
Twardowski, Przemyslaw, Catherine M. Tangen, Xiwei Wu, et al.. (2017). Parallel (Randomized) Phase II Evaluation of Tivantinib (ARQ197) and Tivantinib in Combination with Erlotinib in Papillary Renal Cell Carcinoma: SWOG S1107. PubMed. 1(2). 123–132.
12.
Galsky, Matt D., Noah M. Hahn, Costantine Albany, et al.. (2016). Phase II trial of gemcitabine + cisplatin + ipilimumab in patients with metastatic urothelial cancer.. Journal of Clinical Oncology. 34(2_suppl). 357–357.
13.
Pal, Sumanta K., Jeremy O. Jones, Joanne I. Hsu, et al.. (2012). Clinical outcome in patients receiving systemic therapy for metastatic sarcomatoid renal cell carcinoma: A retrospective analysis☆. Urologic Oncology Seminars and Original Investigations. 31(8). 1826–1831.
14.
Goldkorn, Amir, Nicholas J. Vogelzang, Louis M. Fink, et al.. (2012). Circulating tumor cell (CTC) counts and CTC telomerase activity (TA) as prognotic markers of overall survival (OS) in SWOG S0421: Docetaxel with or without atrasentan for metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology. 30(30_suppl). 1–1.
15.
Longmate, Jeff, David I. Quinn, Kim Margolin, et al.. (2011). A phase II trial of gefitinib and pegylated IFNα in previously treated renal cell carcinoma. International Journal of Clinical Oncology. 16(5). 494–9.
16.
Cheung, Eric, Jacek Pinski, Tanya B. Dorff, et al.. (2009). Oral Fenretinide in Biochemically Recurrent Prostate Cancer: A California Cancer Consortium Phase II Trial. Clinical Genitourinary Cancer. 7(1). 43–50.
17.
Chee, Karen Giselle, Jeff Longmate, David I. Quinn, et al.. (2007). The AKT Inhibitor Perifosine in Biochemically Recurrent Prostate Cancer: A Phase II California/Pittsburgh Cancer Consortium Trial. Clinical Genitourinary Cancer. 5(7). 433–437.
18.
Lara, Primo N., Karen Giselle Chee, Jeff Longmate, et al.. (2004). Trastuzumab plus docetaxel in HER‐2/neu‐positive prostate carcinoma. Cancer. 100(10). 2125–2131.
19.
Lara, Primo N., Przemyslaw Twardowski, & David I. Quinn. (2004). Angiogenesis-Targeted Therapies in Prostate Cancer. PubMed. 3(3). 165–173.
20.
Lara, Primo N., Frederick J. Meyers, Carl Gray, et al.. (2002). HER‐2/neu is overexpressed infrequently in patients with prostate carcinoma. Cancer. 94(10). 2584–2589.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Antoine Thiery-Vuillemin Breakdown of academic impact, for papers by Michael L. Cher Breakdown of academic impact, for papers by Niven Mehra Breakdown of academic impact, for papers by Roberto Iacovelli Breakdown of academic impact, for papers by Begoña Mellado Breakdown of academic impact, for papers by Ulrik Lassen Breakdown of academic impact, for papers by Barbara J. Gitlitz Breakdown of academic impact, for papers by Joshi J. Alumkal Breakdown of academic impact, for papers by Matthew M. Cooney Breakdown of academic impact, for papers by Joaquı́n Mateo